EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 12
Issue: 12
Year: 2025

A REVIEW ON GENE THERAPY FOR HUNTINGTON'S DISEASE

Dr. K. T. Manisenthilkumar*[1], Shubamalya L. G.[2]

[1]Chief Operating Officer(Coo)/HOD -Pharmacy, Royal Care Super Speciality Hospital Coimbatore -62.
[2]Pharm.D, Raos College of Pharmacy, Nellore, AP-524320.

***Corresponding Author: Dr. K. T. Manisenthilkumar**
Chief Operating Officer(Coo)/HOD -Pharmacy, Royal Care Super Speciality Hospital Coimbatore -62.

DOI: https://doi.org/10.5281/zenodo.17746959

How to cite this Article: Dr. K. T. Manisenthilkumar*, Shubamalya L. G. (2025). A REVIEW ON GENE THERAPY FOR HUNTINGTON'S DISEASE. European Journal of Biomedical and Pharmaceutical Sciences, 12(12), 138–149.

Article Received on 03/11/2025 **Article Revised on 24/11/2025** **Article Published on 01/12/2025**

ABSTRACT
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the HTT gene, leading to mutant huntingtin protein aggregation and progressive neuronal loss. Current treatment modalities such as tetrabenazine and supportive measures ameliorate symptoms but are not disease-modifying. Because HD is monogenic, gene therapy has surfaced as an attractive strategy to treat the mutation itself. Herein, we discuss gene silencing methods such as ASOs and RNAi platforms and gene editing platforms indigenously comprising CRISPR/Cas9, zinc finger nucleases, and TALENs. Emphasis is laid upon vectorization systems, which are under extensive investigation looking into safety issues and being able to bypass the blood–brain barrier. Preclinical investigations and early-phase clinical trials (e.g., tominersen, AMT-130) yield positive data with limitations with respect to efficacy and long-term safety. This review discusses the various avenues of gene therapy for HD with a critical emphasis on the potential for disease modification.

KEYWORDS: Huntington's disease, gene therapy, HTT gene, mutant huntingtin protein, antisense oligonucleotides, RNA interference, CRISPR/Cas9, zinc finger nucleases, TALENs, AAV vectors, lipid nanoparticles, neurodegeneration, disease-modifying therapy, clinical trials.

INTRODUCTION
Neurodegenerative disorders consist of a wide range of progressive disease conditions that have one thing in common: selective loss of structure and function of neurons. Common disorders with an increased epidemiology due to the growing aged populations include Alzheimer's disease, Parkinson's disease, crossover lateral sclerosis (Beckers type), and Huntington's disease. The research carried out on glancing away from the diseases led to symptom alleviation, some cases of relieving clinical manifestations, and few attempts to modify the disease itself. Pathological considerations considered protein misfolding, mitochondrial dysfunction, excitotoxicity, and impaired capacity of cell repair being considered some major impediments towards developing a potential therapy that could actually alter the course of the disease.[1,2]

Among neurodegenerative diseases, HD is special because it results from a single mutation in the HTT gene which is inherited in an autosomal manner. This mutation stems from an abnormal expansion of the trinucleotide repeats of CAG that translate into a mutant huntingtin protein manifesting toxic gain-of-function properties. Motor disorders (chorea, dystonia, bradykinesia), cognitive impairment (executive dysfunction, defective memory), and psychiatric disorders (depression, irritability, psychosis) constitute the triad of symptoms his clinical picture comprises. From its monogenic nature arises the presence of a clear molecular target, plus making it a more tractable candidate compared to polygenic or idiopathic neurodegenerative conditions in terms of genetic and molecular therapy.[3,4]

Presently available therapies for HD (tetrabenazine, deutetrabenazine, antipsychotics, antidepressants, and supportive care) are largely symptomatic in nature and

do not alter the course of the disease. With HD progressing inevitably toward severe disability and premature mortality, the search for methods to modify the course of this disease is an urgent and unmet medical need. The classical way of drug development had met with little success in the case of HD because of the blood–brain barrier, systemic toxicity, and the intricate cascade of neuronal dysfunction instigated by the mutant huntingtin protein.[5,6]

The HTT mutation opened the way to targeted therapies to silence, edit, or modify mutant allele expression. Gene therapy is promising for HD as it may intervene directly at the molecular root of the disease rather than treating downstream consequences. Preclinical studies and early clinical trials show that antisense oligonucleotides (ASOs), RNA interference, and CRISPR/Cas9-mediated genome editing provide encouraging results. Meanwhile, delivery vector improvements such as those offered by adeno-associated viruses (AAVs) and lipid nanoparticles process to overcome biological barriers for central nervous system-specific delivery. Through focusing on gene therapy, the research group thereby transforms the approach to HD from symptom relief to long-term modification of the disease and even prevention of onset in the pre-symptomatic carriers.[7]

HISTORY AND DISCOVERY OF HUNTINGTON'S DISEASE

This disease was first comprehensively examined in 1872 by the American physician George Huntington when he published his article, "On Chorea." In this very important paper, he delineated the uniqueness of the condition, which included the fact that it was hereditary, had an adult onset, was progressive in nature, and was characterized by motor symptoms such as involuntary movements and chorea. Because of his observations that distinguished HD from other movement disorders of that time, the disorder was named "Huntington's chorea" to honor his contribution.[8]

While the disease was clinically recognized back in the 1800s, the genetic understanding took the longest time to establish. In the last quarter of the 20th century, linkage studies localized the Huntington gene to the short arm of chromosome 4. The discoveries culminated in 1993 when the Huntington's Disease Collaborative Research Group found the causative mutation-furthered by an unstable expansion of CAG trinucleotide repeats in the HTT gene, coding for the huntingtin protein. This breakthrough changes the landscape for neurogenetic research, as HD went from being one of the poor neurodegenerative disorders-one without a well-established genetic cause-to one with a defined genetic cause.[9]

Afterward, their genetic identification enabled susceptibility genetic testing, better diagnosis, and interventions aimed at therapeutic purposes, especially gene-based therapy. The entire trajectory of HD research, from the clinical observations of George Huntington until today's molecular discoveries, has emphasized HD as a disease to study monogenic neurodegenerative disorders and to develop new genetic therapies.[10]

EPIDEMIOLOGY

Huntington's disease (HD) is a very rare, autosomal-dominant neurodegenerative disorder with variable global prevalence. It is reportedly the commonest among populations of European ancestry, occurring in approximately 5–10 per 100,000 people; however, it is almost non-existent in Asia and Africa (<1 per 100,000), with genetic reasons and underreporting thought to be the contributing factors. A rate of 0.38 per 100,000 person-years has been estimated, with symptom onset typically occurring during the period between 30 and 50 years, though juvenile variety does occur, albeit rarely. Both males and females are equally affected. Greatest influence on age of onset and progression of HD is contributed by the number of CAG repeats in the HTT gene, whilst family history is the major identified risk factor.[11]

GENETIC BASIS OF HUNTINGTON'S DISEASE

Huntington's disease (HD) is a monogenic and autosomal dominant disorder that results from a mutation in the HTT gene located on chromosome 4p16.3. The mutation consists of an abnormal trinucleotide repeat expansion of CAG nucleotides in exon 1, which encodes for a polyglutamine tract in the huntingtin protein.

- **Normal alleles:** ≤26 CAG repeats; no disease.
- **Intermediate alleles:** 27–35 repeats; generally asymptomatic but may expand in offspring.
- **Pathogenic alleles:** ≥36 repeats; associated with disease onset, severity, and progression. Longer repeats typically lead to **earlier onset** and more aggressive disease.

HD has an autosomal dominant inheritance pattern. Every child born to an affected individual has a 50% risk of inheriting the mutation. Genetic anticipation is observed in particular in paternal transmission, where the CAG repeat tends to expand in successive generations, leading to the offspring experiencing symptoms much earlier and much in a more severe manner. This knowledge of the molecular basis is fundamental to genetic counseling, predictive testing, and risk assessment in families affected by HD.[12,13]

PATHOGENESIS OF HUNTINGTON'S DISEASE

Huntington's disease (HD) is caused mainly by the mutation of the HTT gene characterized by an expanded CAG trinucleotide repeat, giving rise to a mutant form of huntingtin protein called mHTT with an abnormally extended polyglutamine tract. This mutation sets in motion a series of molecular and cellular events that culminate in neurodegeneration, especially in the striatum (caudate and putamen) together with the cerebral cortex.

1. Protein Misfolding and Aggregation: Mutant forms of the protein misfold and aggregate inside the cells, forming inclusion bodies in both the nucleus and cytoplasm. They interfere with transcriptional regulation and prevent it from interacting with other proteins necessary for the execution of essential cellular functions.

2. Transcriptional Dysregulation: mHTT alters the activity of transcription factors (like CREB-binding protein, REST/NRSF), thereby decreasing the expression of neuroprotective genes, such as brain-derived neurotrophic factor (BDNF), which is necessary for the survival of striatal neurons.

3. Mitochondrial Dysfunction and Oxidative Stress: mHTT impairs respiration in mitochondria, diminishes ATP synthesis, and enhances ROS formation, causing energy insufficiency and oxidative damage in neuronal cells.[14,15]

4. Excitotoxicity: Striatal neurons are prone to glutamate-mediated excitotoxicity, calcium overload, activation of proteases, and neuronal death.

5. Impaired Proteostasis and Autophagy: Mutant huntingtin disrupts the ubiquitin-proteasome system, as well as autophagic pathways, leading to the accumulation of misfolded proteins and further cellular stress.

6. Synaptic Dysfunction: mHTT changes neurotransmitter release, synaptic vesicle trafficking, and receptor signaling mechanisms, causing early deficits in cognition and psychiatric features before any noticeable neuronal loss occurs.

7. Selective Neuronal Vulnerability: Although mHTT is ubiquitously expressed, the medium spiny neurons in the striatum are most vulnerable, giving rise to typical chorea and motor disturbances. The cortical degeneration, on the other hand, causes the cognitive decline and psychiatric symptoms.

These molecular and cellular disruptions together cause a progressive degeneration of the nervous system, clinically manifesting the motor, cognitive, and psychiatric symptoms. One must get an understanding of these mechanisms to come up with targeted therapies and strategies to silence genes or perhaps protect neurons.[16,17]



SYMPTOMS

Early Stage
- Motor: Subtle clumsiness
- Psychiatric: Irritability, depression, anxiety
- Cognitive: Mild attention & planning deficits

Middle Stage
- Motor: Chorea, dystonia, gait issues
- Psychiatric: Aggression, OCD behaviors
- Cognitive: Memory & judgment decline
- Speech & swallowing difficulties

Late Stage
- Motor: Rigidity, bradykinesia, immobility
- Psychiatric: Severe mood disturbances
- Cognitive: Profound dementia
- Dependence: Full assistance for daily activities[18]



DIAGNOSIS

Diagnostic Component	Purpose / Assessment	Key Findings / Tools
Clinical Evaluation	Assess motor, cognitive, and psychiatric symptoms	- Motor: Chorea, dystonia, bradykinesia (UHDRS scale)- Cognitive: Executive dysfunction, memory deficits- Psychiatric: Depression, irritability, apathy
Genetic Testing	Confirm HTT gene mutation	- CAG trinucleotide repeat analysis- Normal: ≤26 repeats- Intermediate: 27–35 repeats- Reduced penetrance: 36–39 repeats- Full penetrance: ≥40 repeats- Pre-symptomatic testing with counseling
Neuroimaging	Structural and functional brain assessment	- MRI: Striatal atrophy (caudate & putamen)- PET/SPECT: Early metabolic changes in basal ganglia
Biomarkers	Detect neuronal damage and disease burden	- CSF or blood: Mutant huntingtin protein (mHTT), neurofilament light chain (NfL)- Emerging tools for monitoring progression
Electrophysiology	Support functional assessment	- EEG and evoked potentials (non-diagnostic alone)
Differential Diagnosis	Exclude other causes of similar symptoms	- Wilson's disease, tardive dyskinesia, Parkinson's disease, other neurodegenerative disorders[19,20]

CURRENT THERAPEUTIC APPROACHES IN HUNTINGTON'S DISEASE

Since there is presently no therapy capable of curing HD, all interventions are largely symptomatic. Therapeutic interventions try to relieve motor, cognitive, and psychiatric impairments to improve the quality of life along with slowing the progression of the disease, if at all possible.

1. Pharmacological Therapies for Motor Symptoms

A motor dysfunction prominently marked by chorea is the cardinal symptom in HD. Tetrabenazine and deutetrabenazine are the only drugs approved by the FDA in treating chorea. Being presynaptic dopaminergic depleters, they reduce involuntary movements. Antipsychotic agents can also be used to treat chorea and dystonia, especially if psychiatric symptoms are present. The symptomatic benefits of these treatments need to be considered together with their side effects: sedation, parkinsonism, and depression.[21,22]

2. Pharmacological Therapies for Psychiatric Symptoms

Psychiatric symptoms are commonly associated with HD and significantly reduce the patient's quality of life. Antidepressants (SSRIs, SNRIs) will usually be administered when depression and anxiety are present. Antipsychotics will address the more difficult-to-treat symptoms of irritability, aggression, and psychosis. Mood stabilizers-valproate or carbamazepine-are used to control mood swings or impulse behaviors. Treatment requires an individualized approach due to the overlapping motor and psychiatric side effects.[23,24]

3. Cognitive Symptom Management

Cognitive deficits affecting attention, executive function, and memory are difficult to treat. Cholinesterase inhibitors (donepezil) or memantine have been used, but evidence for their efficacy remains limited. Other approaches, such as cognitive rehabilitation and structured routines, with an emphasis on occupational therapy, are able to enhance a patient's ability to function one day at a time as independently as possible.[25]

4. Physical, Occupational, and Speech Therapy
Supportive therapy serves to maintain mobility, coordination, and communication. Physiotherapy targets gait, balance, and strength. Occupational therapy deals with activities of daily living and adaptive equipment, including ensuring safety in the home environment. Speech and swallowing therapy reduce the risks of aspiration and aid in improving nutrition due to dysarthria and dysphagia.

5. Nutritional and Lifestyle Interventions
Patients with HD are usually subjected to loss of weight and have metabolic alteration. It is therefore advisable to provide a high-calorie balanced diet with frequent meals. Exercise should be practiced, as it maintains mobility, cardiovascular health, and general well-being. Lifestyle interventions serve as a complementary treatment to the pharmacological approach to improving the prognosis of the patient.[26,27]

6. Investigational and Disease-Modifying Therapies
Research thrives in targeting the primary genetic and molecular aberrations of Huntington's disease. Gene silencing therapies include antisense oligonucleotides and RNA interference, and gene editing approaches include CRISPR/Cas9 to reduce mutant huntingtin expression. Other experimental approaches involve neuroprotection, stem cells, and modulation of mitochondrial or proteostasis pathways. Thus, all the promising approaches remain in either preclinical or early clinical trial stages.[28]

RATIONALE FOR GENE THERAPY
The clinical phenotype of HD arises from CAG trinucleotide repeat expansions in the HTT gene, which produce a mutated form of huntingtin protein. The mutant protein aggregates in neurons, notably those in the striatum and cortex, leading to progressive neuronal dysfunction, neurodegeneration, and the consequent clinical expression of motor, cognitive, and psychiatric disabilities. Symptomatic treatment, therefore, cannot address this basic genetic problem-and thus gene therapy-that is designed to address the cause-constitutes the revolution in the treatment of HD.

Gene therapy has a remedial effect at the genetic level by suppressing or silencing the expression of the mutant HTT gene. In other words, antisense oligonucleotides (ASOs) or RNAi are approaches to either reduce mHTT production or correct the gene mutation, and gene editing methods, such as CRISPR-Cas9. By removing or correcting the source of neuronal toxicity, this focuses on the potential to slow down or entirely stop neurodegeneration as opposed to merely managing symptomology.[29,30]

Additionally, one should consider the progressive nature of Huntington's disease behind gene therapy. It is well known that mutant Huntington protein (mHTT) begins to accumulate years before actual clinical symptoms appear; in the interim, early intervention at the genetic level could keep neurons from dying and thereby delay disease onset. Another attractive possibility for targeted gene therapy is to provide long-term or maybe even permanent benefits, whereas symptomatic drugs have to be administered continuously. Therefore, this approach may be viewed as a disease-modifying strategy, which will change the natural history of Huntington's disease completely.[31]



STRATEGIES IN GENE THERAPY FOR HUNTINGTON'S DISEASE

In the treatment of HD, gene therapy represents a transformative approach, aiming to alter the underlying mutation as opposed to displaying a mere symptomatic portrayal. Methods used currently include gene silencing, gene editing, and gene replacement or suppression, with each holding its unique mechanism, difficulties, or possibility in disease modification.

1. Gene Silencing Approaches

The goal of gene silencing methods is to reduce the cellular toxicity of the mutant huntingtin (mHTT) protein, with the purpose of its expression.

Antisense Oligonucleotides (ASOs): These are short synthetic strands of nucleic acid, engineered to specifically bind to the mutant huntingtin (HTT) mRNA, leading to its degradation or the inhibition of its translation into protein. By lowering the levels of mutant HTT protein, ASOs try to slow down or stop disease progression. One example is Tominersen (IONIS-HTTRx), shown to be effective in initial trials in lowering HTT protein levels in the cerebrospinal fluid. Although larger studies yielded mixed results later, ASOs remain a leading approach because they attack the disease itself at the RNA level and can be adapted for allele-specific suppression, meaning that they could potentially spare the normal HTT allele.[32]

RNA Interference (RNAi): RNA interference uses small RNA molecules like siRNA, shRNA, or microRNAs to silence mutant HTT post-transcriptionally. They get into the cells via viral vectors or nanoparticles, where they bind to the HTT mRNA and set it for degradation by RISC (RNA-induced silencing complex). The RNAi-based therapeutic approach can be designed for long-term action, especially if delivered via AAV vectors. Preclinical and a few ongoing trials (e.g., AMT-130 by uniQure) have demonstrated the enormous potential of shortening the expression of mutant HTT in neuronal cells for therapeutic aim.[33]

CRISPR/Cas-Mediated Gene Silencing: The CRISPR/Cas system can be modified for gene silencing through CRISPR interference (CRISPRi), apart from performing genome editing. CRISPR/Cas complexes can interfere with the transcription of the mutant HTT gene by targeting its regulatory regions, thereby preventing the formation of mutant protein. Also unlike antisense oligonucleotides (ASOs) or RNA interference mechanisms in which RNA is targeted, CRISPRi confers a more permanent suppression at the DNA level. Yet, the off-target and immune consequences, as well as CNS delivery issues, must be considered prior to any clinical use.[34]

2. Gene Editing Approaches

Gene editing seeks to **directly correct or disrupt the HTT gene**, potentially offering permanent therapeutic benefit.

CRISPR/Cas9 for Correction or Excision of Expanded CAG Repeats: CRISPR/Cas9 is potent in genome editing and directly targets and cleaves a DNA molecule in a defined region. In the context of Huntington's disease, this procedure is undertaken to excise expanded CAG repeats of the HTT gene or to correct the mutation via homology-directed repair. Hence, there might be one curative treatment that is given once by permanently altering the gene for its malfunction. Cellular and animal model studies have proved that CRISPR/Cas9 can reduce mutant HTT expression and restore normal neuronal function. The major challenges staying in the way of therapeutic development are to achieve the required specificity, reduce off-target effects, and efficiently deliver the CRISPR system into the brain cells safely.[35]

Zinc Finger Nucleases (ZFNs): Proteins engineered with the DNA-binding domain fused to a nuclease domain for the cleavage of double-stranded DNA recognizing a defined DNA sequence. For Huntington's disease purposes, ZFNs are designed to cleave the expanded CAG region of the HTT gene and allow its removal or correction by DNA repair pathways. Though less flexible than the CRISPR systems, ZFNs enjoy a high degree of binding specificity and have been trialed for other genetic conditions, theoretically making them a less considered yet promising approach in HD therapeutics. Yet, these therapeutic solutions must face the hurdles of delivery and the engineering of zinc finger proteins for specific sequences.[36]

Transcription Activator-Like Effector Nucleases (TALENs): TALENs resemble ZFNs in function but depend on transcription activator-like effector proteins for DNA recognition, thus providing more flexibility and simpler customization. In Huntington's disease, it is possible to engineer TALENs to cleave near the expanded CAG repeats of the HTT gene, thus facilitating gene correction. Some preclinical studies provide encouraging results in the preferentially selective disruption of the mutant allele, foregoing the wild-type allele. Despite their potential, TALENs face some barriers, such as delivery, large construct size, and less efficiency when compared to CRISPR/Cas9. However, TALENs are still a worthy rival in gene editing.[37]

3. Gene Replacement or Suppression Techniques

These strategies may try to restore normal HTT function or just generally suppress the production of mutant protein.

Delivering Normal HTT Gene Copies: Delivering normal gene copies for HTT in neural cells is one approach for fighting off the toxic effect of the mutant

huntingtin. This strategy would allow compensation in basic cellular functions impaired by the decreased production of wild-type huntingtin. On the other hand, since HTT is a huge gene, a full-length copy of it is very difficult to be packaged and delivered by viral vectors. Present investigations show a conspicuous interest in truncated yet functional forms of HTT, or alternative delivery systems that would bypass this hindrance posed by vector size constraints.[38]

Neurotrophic Factor Delivery (BDNF, GDNF): Genes encoding proteins of neuroprotection could perhaps constitute another promising target for delivery in this regard. These proteins promote neuronal survival, synaptic function, and plasticity and are, therefore, antagonists to neurodegeneration by mutant HTT. BDNF gene delivery has in the past been shown in preclinical experiments to improve motor function and delay neuronal loss in HD models. These treatments do not address the genetic defect directly, but they may be deployed for neuroprotection alongside therapeutic strategies that involve gene silencing or gene editing.[39]

Viral Vector-Based Approaches (AAV, Lentivirus): One of the more critical issues facing gene therapy for Huntington's is the effective delivery of therapeutic genes to the CNS. AAVs and lentiviruses normally serve as vectors since they infect neurons and provide long-term therapeutic gene expression. AAV gene therapy has shown quite promising results in trials for some neurological disorders and is now being adapted to Huntington's to deliver RNAi molecules, ASOs, or genes for neuroprotection. Lentiviral vectors are also being studied because of their stable integration into host DNA, and thus require a safety analysis to minimize insertional mutagenesis.[40]

DELIVERY SYSTEMS FOR GENE THERAPY IN HUNTINGTON'S DISEASE

Efficient and safe delivery of gene therapy agents presents a deciding challenge in HD because it has to do with widespread distribution within the CNS. Current methods have acknowledged both viral and non-viral delivery systems and their relative advantages and limitations.

1. Viral Vectors

These viruses, being nature's own vehicles, have been long considered for gene delivery and are generally found best with respect to efficiency in neuronal transduction and in long-term gene expression.

- **Adeno-Associated Virus (AAV):** AAV is the most commonly used gene delivery system into the CNS because of its low immunogenicity, its ability to infect non-dividing neuronal cells, and for its long-term gene expression. Different serotypes, such as AAV9, cross the blood-brain barrier and can provide a widespread distribution. AAV vectors are employed in RNAi, antisense oligonucleotide, or miRNA constructs for the inhibition of mutant HTT. Clinical manifestations suggested a nice reduction of mHTT with very few adverse effects, but still posed a few considerations of immune reactions and rather limited packaging capability (~4.7 kb).[41]
- **Lentivirus:** Lentiviral vectors can insert into the host genome, thus allowing for stable, long-term expression of therapeutic genes. These are usually applied in preclinical studies in RNAi or gene replacement strategies. Lentiviruses operate on two different types of cells, that is, dividing as well as nondividing cells, but with risk factors, particularly insertional mutagenesis. Proper design should warrant better safety.[42]

2. Non-Viral Delivery Methods

These non-viral systems are being considered to overcome the limitation of viral vectors, being immunogenic and payload limited.

- **Lipid Nanoparticles (LNPs):** LNPs serve to encapsulate RNAi molecules, ASOs, or mRNA molecules destined to be delivered systemically or locally. The system offers biocompatibility and ease of large-scale manufacture with low chances for insertional mutagenesis. Some modifications, such as the addition of surface ligands to LNPs, allow targeting delivery to CNS cells; however, such strategies have yet to show efficient crossing of the blood-brain barrier.[43]
- **Exosomes:** They are natural extracellular vesicles that can overcome the blood-brain barrier to deliver nucleic acids, proteins, or therapeutic RNA molecules to neurons. They offer biocompatibility with minimal immunogenicity as a delivery platform. Such engineered exosomes have been explored in preclinical trials to deliver gene-silencing constructs against HTT. Currently, this is an active field of study with promising preclinical outcomes.[44]

PRECLINICAL STUDIES IN HUNTINGTON'S DISEASE GENE THERAPY

1. Antisense Oligonucleotides (ASOs) and RNA Interference (RNAi)

- **Tominersen (IONIS-HTTRx / RG6042):** In preclinical HD mouse models, Tominersen demonstrated a dose-dependent reduction in mutant huntingtin (mHTT) levels, leading to improved motor function and survival. Notably, these effects were achieved without activating microglia or astrocytes, indicating a lack of significant immune response to the treatment.[45]
- **AAV5-miHTT Constructs:** Studies utilizing AAV5 vectors to deliver microRNA-based constructs targeting mHTT have shown significant suppression of mutant protein levels in HD mouse models. These interventions resulted in amelioration of motor deficits and neuroprotection, supporting the potential of RNAi-based therapies for HD.[46]

2. Gene Editing Approaches

- **CRISPR/Cas9 Systems:** Preclinical studies employing CRISPR/Cas9 technology have successfully targeted and disrupted the expanded CAG repeats in the huntingtin gene in HD mouse models. This gene editing led to a reduction in mHTT levels and associated neurodegeneration, highlighting the therapeutic potential of CRISPR-based interventions for HD.[47]

CLINICAL STUDIES IN HUNTINGTON'S DISEASE GENE THERAPY

1. Tominersen Clinical Trials

- **GENERATION HD1 Trial:** This Phase 3 trial aimed to evaluate the efficacy of Tominersen in early manifest HD patients. However, the study was halted after an interim analysis revealed a lack of improvement in the treated group and potential harm with more intensive therapy.[48]
- **GENERATION HD2 Trial:** Following the discontinuation of GENERATION HD1, the GENERATION HD2 trial was initiated to assess the effects of higher-dose Tominersen in a different cohort. The primary endpoints include safety, changes in cerebrospinal fluid (CSF) levels of mHTT, and functional outcomes.[49]

2. AMT-130 (AAV5-miHTT) Gene Therapy

- **Phase I/II Trials:** AMT-130, an AAV5-based gene therapy delivering a microRNA construct targeting mHTT, has been evaluated in HD patients. Preliminary results indicated a dose-dependent slowing of disease progression, with high-dose recipients showing an 80% reduction in the rate of disease progression compared to controls over 24 months.[50]

3. CRISPR/Cas9-Based Therapies

- **Allele-Specific Editing:** Clinical studies are exploring the use of CRISPR/Cas9 systems for allele-specific targeting of the mutant huntingtin gene. Early-phase trials are focusing on the safety and efficacy of these gene editing approaches in HD patients, aiming to reduce mHTT levels without affecting the wild-type allele.[51]

CHALLENGES AND LIMITATIONS IN HUNTINGTON'S DISEASE GENE THERAPY

1. Delivery Challenges

In the delivery of therapeutic agents to the CNS, efficient delivery remains a foremost challenge. Viral vectors such as AAV or lentivirus have significant limitations to brain-wide distribution, and intrathecal or intracerebral administration being quite invasive. Non-viral means, lipid nanoparticles, or exosomes find it difficult to cross the BBB adequately, thereby inhibiting therapeutics genes from reaching neurons. So, from delivery, the dissemination and uniformity remain questionable with the risk of tissue damage.

2. Immune Responses and Safety Concerns

The immune response to gene therapy vectors can block their activity or induce adverse inflammatory responses. Viral vectors stimulate both innate and adaptive immune responses after administration. While repeated treatment with ASOs or RNAi molecules may trigger systemic or CNS-specific immune responses, off-target effects due to gene editing (CRISPR/Cas9) or RNAi bear a latent risk of gene alteration as well.[52,53]

3. Allele Specificity

Huntington's disease occurs through a dominant mutation of the HTT gene, with the normal allele being critical for neuronal survival. Since gene-silencing approaches in general tend to reduce both mutant and wild-type HTT, there can possibly be unintended neurotoxicity in such instances. Hence, developing allele-specific therapeutics that selectively target the mutant gene while sparing normal HTT is still one of the key technical challenges.

4. Long-Term Efficacy and Monitoring

Sustained mHTT lowering is required for tangible clinical benefits. There is limited long-term efficacy data, and repeat administration may be needed for vectors that do not integrate, such as AAV. Reliable biomarkers (e.g., mHTT, neurofilament light chain) are critical for longitudinal treatment response monitoring but are still being developed.

5. Ethical and Regulatory Considerations

Gene therapy poses certain ethical questions in HD, particularly in pre-symptomatic persons, since interventions could be irreparable. Regulatory approval requires the very stringent demonstration of safety, efficacy, and reproducibility, which is complicated by heterogeneity of disease progression and small patient numbers involved in rare disease trials.

6. Cost and Accessibility

Launching gene therapy drugs is equally very expensive, creating impediments to accessibility for many patients. Even ignoring these high costs, special delivery requirements (e.g., neurosurgical procedure) create further hurdles limiting large-scale clinical implementation.[54,55]

FUTURE PERSPECTIVES IN GENE THERAPY FOR HUNTINGTON'S DISEASE

Improved Delivery Systems

One predominant challenge for targets in gene therapy is delivery to the CNS via the blood-brain barrier and subsequent widespread targeting of neuronal populations. Thus, future development will focus on the development of new viral vectors with improved tropism, the ability to cross the blood-brain barrier (BBB) and lessly, intracerebral, or intrathecal injections in terms of their invasiveness. Non-viral platform-based approaches based on lipid nanoparticles and engineered exosomes are currently being optimized for systemic administrations with better CNS penetration. Targeted delivery using ligand-modified vectors can improve specificity even further, ensuring that vulnerable neuronal populations in the striatum and cortex receive the therapeutic payload.

Allele-Specific and Precision Therapies

Having a wild-type HTT allele is indispensable for the maintenance of normal function in neurons. Gene therapy options in the future are thus expected to carry out allele-specific silencing or editing using SNPs linked to the mutant allele. Advanced RNAi, antisense oligonucleotide, or CRISPR-based treatment regimes are thus expected to selectively downregulate the expression of mutant HTT while preserving the normal allele. Such highly targeted therapies would be better able to treat the HD patient in a very specific manner by reducing off-target effects, the possibility of neurotoxicity, and enhancements in safe long-term use.[56,57]

Combination Therapies

Monotherapy might not suffice to fully arrest the course of the disease; hence, combining therapies might become crucial. Gene-silencing or gene-editing therapeutics could be combined with neuroprotective chemicals, e.g., BDNF, to help protect the neurons against degeneration. Another approach for secondary pathology formed by mutant HTT accumulation is adjunctive treatments that have anti-inflammatory effects, such as those that target stress via oxidants or intermediates of metabolic pathways. Multi-modal therapies can act in synergy with each other to slow disease progression and functional improvement more than just a gene therapy paradigm by itself.

Early Intervention and Pre-symptomatic Treatment

There is evidence suggesting that an early decrease in mutant HTT may halt irreversible neurodegeneration. Future strategies aim to detect subjects in the pre-symptomatic phase of HD and treat them even before clinical manifestations. Reliable biomarkers, for example, cerebrospinal fluid mutant HTT levels and NfL, may be of vital importance to guide patient selection and monitor therapeutic response. An early intervention may delay or even prevent motor, cognitive, and psychiatric symptoms and, thus, change the natural course of the disease.[58,59]

Ethical, Regulatory, and Accessibility Considerations

With the advancements taking place in gene therapies, there arise challenges with ethics and regulations. Interventions occurring before symptoms appear or irreversible interventions on the genome raise ethical questions relating to consent and the risk-benefit balance. Regulatory pathways must ensure patient safety while providing timely access to innovative therapeutics. In addition, barriers to accessibility in terms of cost and complexity of manufacturing, as well as delivery procedures that are highly specialized, should be considered for the therapies to be made equitably available to the larger HD patient population.[60]

CONCLUSION

Huntington's disease remains a formidable neurodegenerative disorder because of its genetic origin and debilitating course. Conventional therapies merely address symptoms but do not modify the disease course, heralding an urgent need for disease-modifying approaches. Gene therapy marks a radical approach by directly addressing the faulty HTT gene. Antisense oligonucleotides, RNA interference, and CRISPR/Cas-based silencing methods have indicated promising outcomes in the downregulation of mutant huntingtin expression, while gene editing tools such as CRISPR/Cas9, ZFNs, and TALENs are able to permanently repair the pathogenic CAG repeat expansion. Simultaneously, neuroprotective gene delivery approaches, including BDNF supplementation and viral vector delivery, provide support for healthy neuronal survival and functioning.

There are still a great many challenges to overcome such as crossing the blood–brain barrier, long-term safety issues, immune-gene therapy methods, and the ethics behind it. As many more cases are now undergoing clinical trials, trials reveal answers about the viability of gene therapies. However, research is slow in the endeavor to ensure their efficacy while minimizing risk. Eventually, precision gene editing, advances in vector technology, and combinational therapeutic strategies may lead gene therapy into becoming a feasible, personalized treatment option for Huntington's disease. Ongoing work has made the prospect of gene therapy slowing down disease progression and potentially modifying the natural course of Huntington's disease real, imparting hope to patients and families being affected by this crushing disorder.

ACKNOWLEDGMENT

A special thanks to Dr. V. Guna Sekharan, Principal, Professor, and Head, Department of Pharmaceutical Chemistry, Rao's College of Pharmacy, Nellore, Andhra Pradesh – 524320, for his valuable guidance, constant encouragement, and inspiring support throughout the preparation of this review article, which greatly contributed to its successful completion.

REFERENCES

1. Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int J Mol Sci., Feb. 6, 2022; 23(3): 1851.
2. Merelli A., Czornyj L., Lazarowski A. Erythropoietin: A neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. Curr. Pharm. Des., 2013; 19: 6791–6801.
3. Shiwal A, Nibrad D, Tadas M, Katariya R, Kale M, Wankhede N, Kotagale N, Umekar M, Taksande B. Polyamines signalling pathway: A key player in unveiling the molecular mechanisms underlying Huntington's disease. Neuroscience, Mar. 27, 2025; 570: 213-224.
4. Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis., Dec. 20, 2010; 5: 40.
5. Saft C, Burgunder JM, Dose M, Jung HH, Katzenschlager R, Priller J, Nguyen HP, Reetz K, Reilmann R, Seppi K, Landwehrmeyer GB. Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society). Neurol Res Pract, Nov. 16, 2023; 5(1): 61.
6. Anderson KE, van Duijn E, Craufurd D, Drazinic C, Edmondson M, Goodman N, Van Kammen D, Loy C, Priller J, Goodman LV. Clinical management of neuropsychiatric symptoms of huntington disease: Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders. Journal of Huntington's Disease, 2018; 7(3): 355–366.
7. Desamericq G, Youssov K, Charles P, Saleh N, Olivier A, Sherer-Gagou C, Verny C, Bachoud-Levi AC. Guidelines for clinical pharmacological practices in Huntington's disease. Revue Neurologique (Paris), 2016; 172(8–9): 423–432.
8. Burgunder, Jean-Marc. Genetics of Huntington’s disease and related disorders: beyond triplet repeats. Ageing and Neurodegenerative Diseases, 2024; 4: 10.
9. Testa CM, Jankovic J. Huntington disease: A quarter century of progress since the gene discovery. J Neurol Sci., Jan. 15, 2019; 396: 52-68.
10. Aqel S, Ahmad J, Saleh I, Fathima A, Al Thani AA, Mohamed WMY, Shaito AA. Advances in Huntington’s Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review. Biology, 2025; 14(2): 129.
11. Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis. Mov Disord, Dec. 2022; 37(12): 2327-2335.
12. Gonzalez Rojas, Natalia, Martin Emiliano Cesarini, Guillermo Peker, Gustavo Andres Da Prat, Jose Luis Etcheverry, & Emilia Mabel Gatto. "Review of Huntingtonâ€™s Disease: From Basics to Advances in Diagnosis and Treatment." Journal of Neurology Research [Online], 2022; 12.3: 93-113.
13. Capiluppi E, Romano L, Rebora P, Nanetti L, Castaldo A, Gellera C, Mariotti C, Macerollo A, Cislaghi MG. Late-onset Huntington's disease with 40-42 CAG expansion. Neurol Sci., Apr. 2020; 41(4): 869-876.
14. Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. Cold Spring Harb Perspect Med., Jul. 5, 2017; 7(7): a024240.
15. Donaldson J, Powell S, Rickards N, Holmans P, Jones L. What is the Pathogenic CAG Expansion Length in Huntington's Disease? J Huntingtons Dis., 2021; 10(1): 175-202.
16. Irfan Z, Khanam S, Karmakar V, Firdous SM, El Khier BSIA, Khan I, Rehman MU, Khan A. Pathogenesis of Huntington's Disease: An Emphasis on Molecular Pathways and Prevention by Natural Remedies. Brain Sci., Oct. 14, 2022; 12(10): 1389.
17. Tong H, Yang T, Xu S, Li X, Liu L, Zhou G, Yang S, Yin S, Li X-J, Li S. Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies. International Journal of Molecular Sciences, 2024; 25(7): 3845.
18. Andhale R, Shrivastava D. Huntington's Disease: A Clinical Review. Cureus, Aug. 27, 2022; 14(8): e28484.
19. Huntington disease. Bates GP, Dorsey R, Gusella JF, et al. Nat Rev Dis Primers., 2015; 1: 15005.
20. Moreira TCG, Paiva CLA, de Andrade Agostinho L. The diagnosis of Huntington's disease by different molecular tools: a systematic review. Expert Rev Mol Diagn, Sep. 2025; 25(9): 621-630.
21. Gulzar M, Kauser S, Khan S, Adnan M, Hassan MI. Therapeutic strategies for Huntington's disease: current approaches and future direction. Neurodegener Dis Manag, 2025; 28: 1-15.
22. Cheng Y, Zhang S, Shang H. Latest advances on new promising molecular-based therapeutic approaches for Huntington's disease. J Transl Int Med., May 21, 2024; 12(2): 134-147.
23. Parish AL, Gillis B, Anthamatten A. Pharmacotherapy for Depression and Anxiety in the Primary Care Setting. J Nurse Pract., Apr. 2023; 19(4): 104556.
24. Gibson JS, Claassen DO. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease. Expert Opin Pharmacother, Jun. 2021; 22(8): 1015-1024.
25. Cani I, Grotteschi N, Calandra-Buonaura G, Guarino M, Guaraldi P, Giannini G, Baldelli L, Donati M, Cortelli P, Camerlingo MD, Nonino F, Sambati L. Efficacy of cholinesterase inhibitors and memantine on symptoms not responsive to levodopa in patients affected by Parkinson's disease without dementia: a systematic review. BMJ Neurol Open, Aug. 3, 2025; 7(2): e001079.
26. Shahid J, Kashif A, Shahid MK. A Comprehensive Review of Physical Therapy Interventions for Stroke Rehabilitation: Impairment-Based Approaches and

Functional Goals. Brain Sci., Apr. 25, 2023; 13(5): 717.
27. Gaba A. Nutrition and Huntington's Disease- A Review of Current Practice and Theory. Curr Nutr Rep., Jan. 16, 2025; 14(1): 18.
28. Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol. 2017 Oct; 16(10): 837-847. doi: 10.1016/S1474-4422(17)30280-6. Epub 2017 Sep 12. Erratum in: Lancet Neurol, Dec. 2017; 16(12): 954.
29. Tong H, Yang T, Xu S, Li X, Liu L, Zhou G, Yang S, Yin S, Li XJ, Li S. Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies. Int J Mol Sci., Mar. 29, 2024; 25(7): 3845.
30. Jurcau A, Jurcau MC. Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy. Biomedicines, 2022; 10(8): 1895.
31. Jurcau A, Jurcau MC. Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy. Biomedicines, Aug. 5, 2022; 10(8): 1895.
32. Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, Bahal R. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J Clin Med., Jun. 26, 2020; 9(6): 2004.
33. Aguiar S, van der Gaag B, Cortese FAB. RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA. Transl Neurodegener, Nov. 27, 2017; 6: 30.
34. Kolli N, Lu M, Maiti P, Rossignol J, Dunbar GL. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease. Int J Mol Sci., Apr. 2, 2017; 18(4): 754.
35. Qin Y, Li S, Li XJ, Yang S. CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy. Neurosci Bull., Nov. 2022; 38(11): 1397-1408.
36. Alkanli SS, Alkanli N, Ay A, Albeniz I. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease. Mol Neurobiol, Mar. 2023; 60(3): 1486-1498.
37. Fink KD, Deng P, Gutierrez J, Anderson JS, Torrest A, Komarla A, Kalomoiris S, Cary W, Anderson JD, Gruenloh W, Duffy A, Tempkin T, Annett G, Wheelock V, Segal DJ, Nolta JA. Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts. Cell Transplant, 2016; 25(4): 677-86.
38. Piao X, Li D, Liu H, Guo Q, Yu Y. Advances in gene and cellular therapeutic approaches for Huntington's disease. Protein Cell, May 28, 2025; 16(5): 307-337.
39. Azman KF, Zakaria R. Brain-Derived Neurotrophic Factor (BDNF) in Huntington's Disease: Neurobiology and Therapeutic Potential. Curr Neuropharmacol, 2025; 23(4): 384-403.
40. Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther., May 2008; 16(5): 947-56.
41. Helal MM, Ibrahim AA, Beddor A, Kashbour M. Breaking Barriers in Huntington's Disease Therapy: Focused Ultrasound for Targeted Drug Delivery. Neurochem Res., Jan. 3, 2025; 50(1): 68.
42. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz), Apr. 2010; 58(2): 107-19.
43. Mukai H, Ogawa K, Kato N, Kawakami S. Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics. Drug Metab Pharmacokinet, Jun. 2022; 44: 100450.
44. Sanadgol N, Abedi M, Hashemzaei M, Kamran Z, Khalseh R, Beyer C, Voelz C. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. J Nanobiotechnology, Jun. 18, 2025; 23(1): 453.
45. Sarah J. Tabrizi. Targeting Huntingtin Expression in Patients with Huntington's Disease. N Engl J Med., 2019; 380: 2307-2316.
46. Evers MM, Miniarikova J, Juhas S, Vallès A, Bohuslavova B, Juhasova J, Skalnikova HK, Vodicka P, Valekova I, Brouwers C, Blits B, Lubelski J, Kovarova H, Ellederova Z, van Deventer SJ, Petry H, Motlik J, Konstantinova P. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model. Mol Ther., Sep. 5, 2018; 26(9): 2163-2177.
47. Alkanli SS, Alkanli N, Ay A, Albeniz I. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease. Mol Neurobiol, Mar. 2023; 60(3): 1486-1498.
48. Genentech Provides Update on Tominersen Program in Manifest Huntington's Disease https://www.gene.com/media/press-releases/14902/2021-03-22/genentech-provides-update-on-tominersen-?utm_source=chatgpt.com
49. GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose https://www.neurologylive.com/view/generation-hd2-trial-huntington-agent-tominersen-amended-include-only-higher-dose
50. The First Domino Falls: AMT-130 Gene Therapy Slows Huntington's in Landmark Trial https://en.hdbuzz.net/the-first-domino-falls-amt-130-gene-therapy-slows-huntingtons-in-landmark-trial/
51. Abad-Sojos S, Torres O, Ordóñez KL. Application of the technique CRISPR/Cas9 in the reduction and permanent inactivation of Huntington's disease. Aplicación de la técnica CRISPR / Cas9 en la reducción e inactivación permanente de la enfermedad de Huntington. News Views, 2018; 3: 689–691.

52. Byun S, Lee M, Kim M. Gene Therapy for Huntington's Disease: The Final Strategy for a Cure? J Mov Disord, Jan. 2022; 15(1): 15-20.
53. Puhl DL, D'Amato AR, Gilbert RJ. Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain Res Bull., Aug. 2019; 150: 216-230.
54. Zhang Y, Engelman J, Friedlander RM. Allele-specific silencing of mutant Huntington's disease gene. J Neurochem, Jan. 2009; 108(1): 82-90.
55. Anderson WF. Human gene therapy: scientific and ethical considerations. J Med Philos., Aug. 1985; 10(3): 275-91.
56. Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A. Current and Possible Future Therapeutic Options for Huntington's Disease. J Cent Nerv Syst Dis., May 21, 2022; 14: 11795735221092517.
57. Maguire CA, Ramirez SH, Merkel SF, Sena-Esteves M, Breakefield XO. Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics, 2014; 11(4): 817-39.
58. Paul A, Collins MG, Lee HY. Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders. Front Genome Ed., Jun. 22, 2022; 4: 899209.
59. Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease. Neuron, Mar. 6, 2019; 101(5): 801-819. Erratum in: Neuron, May 22, 2019; 102(4): 899.
60. Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, Muñoz-Sanjuan I, Sampaio C, Rosser AE, Leavitt BR. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol, Jul. 2022; 21(7): 645-658.